Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

China Releases New Edition Of Chinese Pharmacopeia, Bringing The Country One Step Closer To Global Standards

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - China's State FDA announced Oct. 10 that compilation of the new Chinese Pharmacopeia 2010 edition has been completed and will be implemented July 1, 2010. The new edition covers more than 4,600 kinds of medicines

You may also be interested in...



China Releases Strictest Ever GMP Draft Guidelines; Laxer Standards Urged For Local Companies

SHANGHAI - China's State FDA recently published a new draft version of Good Manufacturing Practice guidelines for pharmaceuticals on its website for public comment

FDA Identifies Excipients At Risk for Potential Melamine Contamination; Issues Alert That New USP Standards for Heparin Products Will Result in Decreased Potency

FDA officials have alerted pharmaceutical manufacturers and suppliers of 23 drug excipients that may be at risk for melamine contamination and outlined certain compendial and non-compendial procedures to follow for better detecting its presence

Safety Of Traditional Chinese Medicine Injections Questioned Following Three Deaths

SHANGHAI - Three deaths caused by adverse drug reactions allegedly linked to use of herbal injection Shuanghuanglian have raised wider concerns over the safety of herbal injections in China

Related Content

Latest News
See All
UsernamePublicRestriction

Register

SC070064

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel